These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 37052887)
1. Revision of potential prognostic markers of cholangiocarcinoma for clinical practice. Saengboonmee C; Obchoei S; Sawanyawisuth K; Wongkham S Expert Rev Anticancer Ther; 2023 May; 23(5):517-530. PubMed ID: 37052887 [TBL] [Abstract][Full Text] [Related]
2. Prognostic biomarkers for cholangiocarcinoma and their clinical implications. Saengboonmee C; Sawanyawisuth K; Chamgramol Y; Wongkham S Expert Rev Anticancer Ther; 2018 Jun; 18(6):579-592. PubMed ID: 29676221 [TBL] [Abstract][Full Text] [Related]
3. Identification and validation of a novel ferroptosis-related gene signature for prognosis and potential therapeutic target prediction in cholangiocarcinoma. Sae-Fung A; Mutirangura A; Jitkaew S Front Immunol; 2022; 13():1051273. PubMed ID: 36733386 [TBL] [Abstract][Full Text] [Related]
4. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma. Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275 [TBL] [Abstract][Full Text] [Related]
6. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management. Walter D; Hartmann S; Waidmann O Z Gastroenterol; 2017 Jun; 55(6):575-581. PubMed ID: 28376540 [TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Macias RIR; Cardinale V; Kendall TJ; Avila MA; Guido M; Coulouarn C; Braconi C; Frampton AE; Bridgewater J; Overi D; Pereira SP; Rengo M; Kather JN; Lamarca A; Pedica F; Forner A; Valle JW; Gaudio E; Alvaro D; Banales JM; Carpino G Gut; 2022 Aug; 71(8):1669-1683. PubMed ID: 35580963 [TBL] [Abstract][Full Text] [Related]
8. Cholangiocarcinoma combined with biliary obstruction: an exosomal circRNA signature for diagnosis and early recurrence monitoring. Wen N; Peng D; Xiong X; Liu G; Nie G; Wang Y; Xu J; Wang S; Yang S; Tian Y; Li B; Lu J; Cheng N Signal Transduct Target Ther; 2024 May; 9(1):107. PubMed ID: 38697972 [TBL] [Abstract][Full Text] [Related]
9. A novel prognostic biomarker for cholangiocarcinoma: circRNA Cdr1as. Jiang XM; Li ZL; Li JL; Xu Y; Leng KM; Cui YF; Sun DJ Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):365-371. PubMed ID: 29424892 [TBL] [Abstract][Full Text] [Related]
10. KIF4A as a novel prognostic biomarker in cholangiocarcinoma. Zhang DY; Ma SS; Sun WL; Lv XCH; Lu Z Medicine (Baltimore); 2021 May; 100(21):e26130. PubMed ID: 34032761 [TBL] [Abstract][Full Text] [Related]
11. Current approaches to the diagnosis and treatment of cholangiocarcinoma. Reddy SB; Patel T Curr Gastroenterol Rep; 2006 Feb; 8(1):30-7. PubMed ID: 16510032 [TBL] [Abstract][Full Text] [Related]
12. Novel approaches in search for biomarkers of cholangiocarcinoma. Mocan LP; Ilieș M; Melincovici CS; Spârchez M; Crăciun R; Nenu I; Horhat A; Tefas C; Spârchez Z; Iuga CA; Mocan T; Mihu CM World J Gastroenterol; 2022 Apr; 28(15):1508-1525. PubMed ID: 35582128 [TBL] [Abstract][Full Text] [Related]
13. A review of the clinical diagnosis and therapy of cholangiocarcinoma. Yao D; Kunam VK; Li X J Int Med Res; 2014 Feb; 42(1):3-16. PubMed ID: 24366497 [TBL] [Abstract][Full Text] [Related]
16. Prognostic biomarkers for cholangiocarcinoma (CCA): state of the art. Lang SA; Bednarsch J; Joechle K; Amygdalos I; Czigany Z; Heij L; Ulmer TF; Neumann UP Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):497-510. PubMed ID: 33970740 [No Abstract] [Full Text] [Related]
17. Circulating microRNA-21 as a prognostic, biological marker in cholangiocarcinoma. Liu CH; Huang Q; Jin ZY; Xie F; Zhu CL; Liu Z; Wang C J Cancer Res Ther; 2018 Jan; 14(1):220-225. PubMed ID: 29516989 [TBL] [Abstract][Full Text] [Related]
18. Serum and bile biomarkers for cholangiocarcinoma. Alvaro D Curr Opin Gastroenterol; 2009 May; 25(3):279-84. PubMed ID: 19396965 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of a panel of cancer stem cell markers enhances the predictive capability of the progression and recurrence in the early stage cholangiocarcinoma. Padthaisong S; Thanee M; Namwat N; Phetcharaburanin J; Klanrit P; Khuntikeo N; Titapun A; Sungkhamanon S; Saya H; Loilome W J Transl Med; 2020 Feb; 18(1):64. PubMed ID: 32039729 [TBL] [Abstract][Full Text] [Related]
20. Biomarkers of intrahepatic cholangiocarcinoma: diagnosis and response to therapy. Brown ZJ; Hewitt DB; Pawlik TM Front Biosci (Landmark Ed); 2022 Mar; 27(3):85. PubMed ID: 35345317 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]